BioSpace News Archive

Edgewise Therapeutics, Inc., (Nasdaq: EWTX) announced today positive 12-month topline results from the ongoing ARCH study, an open label, single-center study assessing the safety, tolerability, impact on muscle damage biomarkers, and pharmacokinetics (PK) of EDG-5506 in adults with BMD.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 11,800 shares of the Company’s common stock at an exercise price per share of $19.24, which was the closing price on June 23, 2023, and restricted stock units to acquire a total of 5,900 shares of the Company’s common stock.

Invacare Holdings Corporation, announced that it has appointed Kai Zhu as Senior Vice President and Chief Financial Officer, effective July 1, 2023.

Novanta Inc. (Nasdaq: NOVT) (the “Company”) announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at the CJS Securities 23rd Annual New Ideas Summer Conference on Tuesday, July 11, 2023, in White Plains, New York.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced the publication of positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor® in newborn infants, published in the journal Pediatric Drugs.

RefleXion Medical, Inc. today announced that results of a prospective investigator-initiated clinical imaging study conducted on its X1 platform by City of Hope using positron emission tomography (PET) were presented on June 24 during an oral session at the Society of Nuclear Medicine and Medical Imaging (SNMMI) annual meeting in Chicago.

Amyris, Inc. announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately.

Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering cell therapies targeting oncology and other diseases, today announced it has completed a Pre-Investigational New Drug (“Pre-IND”) meeting with the FDA.

Makana™ Therapeutics announced that it has been awarded an Artificial Kidney Phase II Prize from KidneyX to continue development of its genetically engineered donor pigs for use in kidney transplantation.

Enzolytics, Inc., a drug development biotech company, provided an update regarding Virogentics, Inc.'s ITV-1 African Project.